PROTEOSTASIS THERAPEUTICS IN's ticker is PTI and the CUSIP is 74373B109. A total of 60 filers reported holding PROTEOSTASIS THERAPEUTICS IN in Q2 2019. The put-call ratio across all filers is 20.98 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $131,000 | +89.9% | 119,284 | +138.2% | 0.02% | -42.1% |
| Q2 2020 | $69,000 | -63.5% | 50,073 | -69.8% | 0.04% | -19.1% |
| Q1 2020 | $189,000 | +21.2% | 165,565 | -10.5% | 0.05% | +123.8% |
| Q3 2019 | $156,000 | -12.4% | 184,955 | +1.6% | 0.02% | +5.0% |
| Q2 2019 | $178,000 | – | 181,974 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 3,804,027 | $17,803,000 | 2.95% |
| HARBOURVEST PARTNERS LLC | 440,627 | $2,062,000 | 0.89% |
| NEA Management Company, LLC | 3,556,778 | $16,646,000 | 0.61% |
| Rock Springs Capital Management LP | 450,000 | $2,106,000 | 0.11% |
| Bain Capital Public Equity Management, LLC | 263,498 | $1,233,000 | 0.07% |
| ELEMENT CAPITAL MANAGEMENT LLC | 65,973 | $309,000 | 0.06% |
| Hillhouse Capital Management | 865,923 | $4,053,000 | 0.06% |
| SABBY MANAGEMENT, LLC | 125,151 | $586,000 | 0.04% |
| Marshall Wace North America L.P. | 684,124 | $3,421,000 | 0.02% |
| FNY Partners Fund LP | 20,127 | $94,000 | 0.02% |